Docon Technologies Private Limited (“Docon”), Promoter of Thyrocare Technologies has sold 53,32,860 equity shares of the Company through market trades on 24th October 2025 for an aggregate gross consideration of ₹. 667.69 crore (rounded off), at an average price of approximately ₹. 1,252.03 per share (rounded off).
The number of shares sold constitutes approximately 10% of the total paid-up capital of the Company. Following this transaction, Docon continues to be a promoter of the Company. Post this transaction, the promoter shareholding in the Company stands reduced to 60.93% from the pre-transaction shareholding of 70.98%.